Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB928-based combination therapy platform study in metastatic colorectal cancer
2024-511158-36-00Phase 2Completed
- Sponsor
- Arcus Biosciences
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of etrumadenant, quemliclustat and zimberelimab in colorectal adenocarcinoma (3 cohorts), sponsored by Arcus Biosciences. Primary endpoints: Progression-free survival, Objective response rate and 1 more. Started Aug 2021; status: completed.
02
Drugs
etrumadenantquemliclustatzimberelimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2024-511158-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511158-36-00.